Insights into Patient Experiences with Facilitated Subcutaneous Immunoglobulin Therapy in Primary Immune Deficiency: A Prospective Observational Cohort

• DOI: 10.1007/s10875-024-01771-0
• Publication Date: 2024-08-05T01:01:46Z
• Authors: Ezgi Yalcin Gungoren; Melek Yorgun Altu...; Ummugulsum Dikici; Zeynep Meric; Isil Eser Simsek; Ayca Kiykim; Salim Can; Esra Karabiber; Nalan Yakici; Fazil Orhan; Haluk Cokugras; Metin Aydogan; Oner Ozdemir; Sevgi Bilgic Eltan; Safa Baris; Ahmet Ozen; Elif Karakoc-Aydiner
• Keywords: Medical microbiology; Primary Immunodeficiency

Immunoglobulin G replacement therapy (IgRT), intravenous (IV) and subcutaneous (SC) routes, is pivotal in treatment of primary immunodeficiencies (PID). In recent years, facilitated immunoglobulin (fSCIG), a combination rHuPH20 10% IgG has emerged as delivery method to combine advantages both IV SC.